Literature DB >> 1847698

Adenosine and 2-phenylaminoadenosine (CV-1808) inhibit human neutrophil bactericidal function.

G E Hardart1, G W Sullivan, H T Carper, G L Mandell.   

Abstract

Adenosine is a natural autocoid and immunomodulator that serves an anti-inflammatory role. Stimulation of polymorphonuclear neutrophils (PMN) with soluble stimuli has been shown to inhibit the PMN oxidative burst. We examined the effects of adenosine and the adenosine analog 2-phenylaminoadenosine (CV-1808) on PMN bactericidal function. Adenosine (10 mM) and CV-1808 (10 to 100 microM) inhibited PMN killing of Staphylococcus aureus. There were more surviving bacteria after 240 min of incubation of PMN with S. aureus and adenosine (10 mM) or CV-1808 (100 microM) (254% +/- 45% and 739% +/- 88% of control, respectively) (P less than 0.05) than there were in the control. In contrast, inosine (10 mM), the major degradation product of adenosine, did not affect killing. Adenosine and CV-1808 did not alter cell association of S. aureus, but S. aureus-activated PMN superoxide release was decreased by adenosine (10 microM) and CV-1808 (10 microM) to 67% +/- 7% and 32% +/- 12% that of the control, respectively (P less than 0.05). Since adenosine inhibited PMN bactericidal function only at approximately 10,000 times peak physiological concentrations, endogenous adenosine levels would not be expected to adversely affect PMN bactericidal function. On the other hand, pharmacological concentrations of adenosine derivatives may decrease the oxidative burst and killing sufficiently to increase host susceptibility to infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847698      PMCID: PMC258343          DOI: 10.1128/iai.59.3.885-889.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Adenosine: emerging role as an immunomodifying agent.

Authors:  G M Kammer
Journal:  J Lab Clin Med       Date:  1987-09

Review 2.  Current concepts: immunology. Neutrophils in human diseases.

Authors:  H L Malech; J I Gallin
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

3.  Suppression of human polymorphonuclear leukocyte phagocytosis by adenosine analogs.

Authors:  Y Nishida; Z Honda; T Miyamoto
Journal:  Inflammation       Date:  1987-09       Impact factor: 4.092

Review 4.  Cardiovascular effects of adenosine in man; possible clinical implications.

Authors:  A Sollevi
Journal:  Prog Neurobiol       Date:  1986       Impact factor: 11.685

Review 5.  Adenosine receptors in the central nervous system: relationship to the central actions of methylxanthines.

Authors:  J W Daly; R F Bruns; S H Snyder
Journal:  Life Sci       Date:  1981-05-11       Impact factor: 5.037

6.  Subclasses of external adenosine receptors.

Authors:  C Londos; D M Cooper; J Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

7.  The effects of adenosine agonists on human neutrophil function.

Authors:  D J Schrier; K M Imre
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

8.  Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes.

Authors:  W L Hand; D L Hand; N L King-Thompson
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

9.  Phagocyte impotence caused by an invasive bacterial adenylate cyclase.

Authors:  D L Confer; J W Eaton
Journal:  Science       Date:  1982-09-03       Impact factor: 47.728

10.  Inhibition by adenosine of reactive oxygen metabolite production by human polymorphonuclear leucocytes.

Authors:  P A Roberts; A C Newby; M B Hallett; A K Campbell
Journal:  Biochem J       Date:  1985-04-15       Impact factor: 3.857

View more
  2 in total

1.  Tsetse fly saliva accelerates the onset of Trypanosoma brucei infection in a mouse model associated with a reduced host inflammatory response.

Authors:  Guy Caljon; Jan Van Den Abbeele; Benoît Stijlemans; Marc Coosemans; Patrick De Baetselier; Stefan Magez
Journal:  Infect Immun       Date:  2006-09-05       Impact factor: 3.441

Review 2.  Purinergic signalling and immune cells.

Authors:  Geoffrey Burnstock; Jean-Marie Boeynaems
Journal:  Purinergic Signal       Date:  2014-10-29       Impact factor: 3.765

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.